Written Answers Nos. 237-256
237. Deputy Fionntán Ó Súilleabháin asked the Minister for Health when the ten-bed specialised community mental health unit will be delivered for County Wexford; if this unit will provide service to adults and minors; if this unit will specialise in mental health crisis care; and if she will make a statement on the matter. [17255/26]
View answerThe Department of Health are leading work to develop a 10-year Capital Plan for Mental Health Services, and as part of this work the need for a new mental health facility in Wexford has been identified. In anticipation of progressing a new proposal, the HSE is currently reviewing current and future service needs for the Wexford area, and a scoping exercise is being established based on updated service requirements. A strategy will be developed and progressed in line with HSE Protocols and Infrastructure Guidelines.
I have included the development of an initial 10-bed specialist community mental health facility for Wexford in the Capital Plan 2026 following consultation with the Integrated Healthcare Area manager for Waterford / Wexford and the Executive Clinical Director for the region.
I will be publishing the 10 year capital plan in 2026.
As this is a service matter, I have asked the Health Service Executive to respond directly to the Deputy as soon as possible.
238. Deputy Richard O'Donoghue asked the Minister for Health the reason a respite centre, has been closed to families receiving respite care (details supplied); and if she will make a statement on the matter. [17257/26]
View answerAs this is a service matter, I have asked the Health Service Executive to respond to the Deputy directly, as soon as possible.
239. Deputy Sorca Clarke asked the Minister for Health the number of opticians currently providing services in the HSE in Mullingar; and if she will make a statement on the matter. [17259/26]
View answerAs this is a service matter, I have asked the Health Service Executive to respond to the Deputy directly, as soon as possible.
240. Deputy William Aird asked the Minister for Health if she will include the shingrix (shingles) vaccine in the HSE’s covered vaccine schedule, particularly for immunocompromised patients; and if she will make a statement on the matter. [17262/26]
View answerThe immunisation programme in Ireland is based on the advice of the National Immunisation Advisory Committee (NIAC). NIAC considers the prevalence of the relevant disease in Ireland as well as international best practice in relation to immunisation when developing its advice.
The current NIAC guidelines state that the shingles vaccine may be considered for those aged 65 years and older, due to the greater burden and severity of disease in this age group and in those aged 18 years and older at increased risk of shingles.
The Health Information and Quality Authority (HIQA) has carried out a Health Technology Assessment (HTA) on the herpes zoster vaccine which protects against shingles. A HTA is a multidisciplinary research process that collects and summarises information about a health technology. HIQA’s HTA examined the evidence on the clinical effectiveness and safety of shingles vaccines. The cost effectiveness and budget impact were also reviewed, along with the ethical, social and organisational implications of including the vaccine in the adult immunisation schedule.
HIQA published this HTA on 19 July 2024. The HTA found that adding the shingles vaccine to the routine immunisation schedule, at the vaccine price at the time, for all adults aged 65 years and over would not be cost effective and would be associated with a substantial budget impact.
While the vaccine is considered safe and effective, its protective effect diminishes over time. HIQA also noted the substantial budget impact associated with vaccination. If made available to everyone aged 65 and older, vaccination would cost €218 million over five years.
Whilst the HTA found that the introduction of the shingles vaccine was not cost effective based on the cost of the vaccine, it found that it could be cost effective for vaccination of those at 75 years and 80 years if the cost of the vaccine was reduced by 80%.
Given that the healthcare budget is finite and decisions regarding increased spending relating to a change in one area could impact the provision of other health technologies and treatments within the healthcare system, the cost-effectiveness must be considered in any decision-making process.
My Department considered the findings of this HTA in 2024 and determined that the introduction of the vaccine could be reconsidered when the cost effectiveness of the vaccine is confirmed as being more favourable.
I can confirm that the introduction of the shingles vaccine to the immunisation schedule in Ireland is again being actively considered for a cohort of immunocompromised individuals, in line with NIAC advice and cognisant of the cost effectiveness of market pricing and available funding.
241. Deputy William Aird asked the Minister for Health the steps being taken to expand the delivery of hearing and eye care services in community settings; her plans to increase the role of primary and community care providers in improving access to these services; and if she will make a statement on the matter. [17263/26]
View answer242. Deputy William Aird asked the Minister for Health the assessment that has been made of the barriers faced by older people and other vulnerable groups in accessing hearing care services, including cost, waiting times and geographic availability; the actions planned to address these barriers; and if she will make a statement on the matter. [17264/26]
View answerI propose to take Questions Nos. 241 and 242 together.
The National Hearing Care Plan Working Group was established in August 2024. The Group is jointly chaired by the Department of Health and the Health Service Executive (HSE). Membership of the Working Group is drawn from relevant stakeholders, including HSE clinicians and management, the Irish Society of Hearing Aid Audiologists (ISHAA), the Irish Academy of Audiology (IAA), and the Department of Social Protection.
The Working Group has been tasked with developing recommendations for a holistic model of hearing care in Ireland. To support this, a structured workstream has been developed, including subgroups focused on progressing priority issues. Significant progress has been made to date. There have been 21 meetings of the Working Group and associated subgroups since formation.
The scope of the work being considered by the Group has expanded beyond initial expectations, which has impacted on the timeline of the delivery of the report. The Group saw this as an opportunity to deliver a more comprehensive plan that considers all aspects of audiology care, thus ensuring the greatest benefit to patients.
A public consultation process is due to commence later this month, with a final National Hearing Care Plan due for the Minister’s consideration in Q2 2026. The public consultation will provide valuable insight into barriers that patients face when trying to access hearing care services.
In the meantime, I have allocated €750,000 for an initiative to support the HSE to utilise external providers to reduce the number of children waiting.
This funding will be used for children over the age of 4 who have been waiting longer than 1 year. Most of these children should be able to be tested by a single audiologist. However, some of them may require a second assessment.
As of December 2025, 601 children over 4 years of age were removed from the Audiology Paediatric Waiting List. The €750,000 that was allocated in Budget 2025 is now recurring and the HSE have advised that over 3,500 children will be seen in 2026.
The HSE provides optical services free of charge to pre-school children and national school children referred from child health service and school health service examinations who are discovered to have sight problems. These children are referred to the appropriate service for treatment. In such circumstances, these services will continue to be provided until the child has reached the age of 16.
The Community Ophthalmic Services Scheme (COSS) is a national fee-per-item scheme which was introduced in 1979. Under the COSS, medical card holders aged over 16 years can be seen by ophthalmologists, community ophthalmic physicians, optometrists or dispensing opticians.
The HSE Primary Care Eye Services Review Group Report, published in 2017, estimated that 60% of existing outpatient activity could be moved to primary care thus enabling hospital services to focus on patients who require more specialist diagnostics or treatments.
The National Clinical Programme for Ophthalmology, published in 2017, developed a model of care detailing how the realignment of eye services from an acute hospital setting to the community would be undertaken.
The HSE has been developing multidisciplinary Integrated Eye Care Teams in accordance with this model of care. These teams facilitate assessment, diagnoses, management and treatment, and, in some cases, pre-op/post-op care, enabling most patients to be seen in their own locality. Where necessary, patients can be referred onwards to acute Ophthalmology services to receive the necessary specialist input.
Transferring the routine care of children aged 8+ years to the care of local private optometrists remains a priority. Work is also ongoing to explore the best way to expand the scope of practice of optometrists so that they can do more in their daily practice.
The Programme for Government: Securing Ireland’s Future contains a commitment to review the National Clinical Programme for Ophthalmology to ensure more eye services are provided in the community. Engagement with relevant stakeholders regarding this is ongoing.
243. Deputy William Aird asked the Minister for Health if she intends to establish the joint working group proposed at the Joint Oireachtas Committee on Health, comprising CORU, organisations (details supplied), academic institutions, service users to examine improvements to CORU regulatory standards; if community-based therapy providers, including section 39 and section 56 organisations funded by Tusla, the HSE and other agencies, will be formally included; the timeline for the group’s establishment and first meeting; and if she will make a statement on the matter. [17265/26]
View answerAs the Deputy is aware, CORU is Ireland’s multi-profession health and social care regulator and was established under the 2005 Act. CORU’s role is to protect the public by regulating the health and social care professions designated under the Health and Social Care Professionals Act 2005 (as amended).
CORU’s Counsellors and Psychotherapists Registration Board was established in 2019 and since then has been working to progress regulation of both professions.
CORU has undertaken very significant research and stakeholder engagement at all stages of the process to regulate counsellors and psychotherapists and continues to engage with all stakeholders as it moves towards the regulation of these professions.
In July 2025 CORU published two key documents for each of these professions:
For each profession there is:
• Standards of Proficiency, which set out the minimum knowledge and skills required for entry to the Register.
• Criteria for Education and Training Programmes, which set the requirements for how professional training programmes are designed and managed to ensure graduates consistently meet the Standards of Proficiency.
These requirements set out the level of education and clinical training needed to practise safely and effectively. Ireland is now the first country in the world to establish distinct regulatory standards for entry to both professions. Setting these standards has now laid the foundations so education programmes can be designed to ensure consistency of education and training and the standards for entry into practice for both professions.
As you might be aware the Irish Council for Psychotherapy (ICP) and the Irish Association for Counsellors and Psychotherapists (IACP) and CORU, appeared before the Joint Committee on Health (JCH) in November in relation to the draft Standards and Criteria.
The Chair of the JCH subsequently wrote to me, requesting a pause in the regulation of counsellors and psychotherapists to enable further consideration or mediation to be undertaken.
I met with the IACP and ICP this week to hear their concerns and I will be responding to the Chair of the JCH shortly.
244. Deputy William Aird asked the Minister for Health the number of WTE consultant orthopaedic surgeons based at Portlaoise Regional Hospital as of 26 February 2026, in tabular form; and if she will make a statement on the matter. [17266/26]
View answerAs this is a service matter, I have asked the Health Service Executive to respond to the Deputy directly, as soon as possible.
245. Deputy William Aird asked the Minister for Health the staffing budget for Midlands Regional Hospital Portlaoise in 2024, 2025 and 2026, in tabular form; and if she will make a statement on the matter. [17267/26]
View answerAs this is a service matter, I have asked the Health Service Executive to respond to the Deputy directly, as soon as possible.
246. Deputy William Aird asked the Minister for Health the number of agency staff employed by Midlands Regional Hospital, Portlaoise across all departments, in tabular form; and if she will make a statement on the matter. [17268/26]
View answerAs this is a service matter, I have asked the Health Service Executive to respond to the Deputy directly, as soon as possible.
247. Deputy William Aird asked the Minister for Health the number of WTE consultant psychiatrists attached to Laois mental health services as of 26 February 2006; and if she will make a statement on the matter. [17269/26]
View answerAs this is a service matter, I have asked the Health Service Executive to respond to the Deputy directly, as soon as possible.
248. Deputy William Aird asked the Minister for Health if she will include acarizax on the reimbursement list of medicines; and if she will make a statement on the matter. [17270/26]
View answerUnder the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.
249. Deputy Ciarán Ahern asked the Minister for Health the reason Skyclarys has not yet been approved for reimbursement despite being authorised for use by the European Medicines Agency; and if she will make a statement on the matter. [17273/26]
View answer250. Deputy Ciarán Ahern asked the Minister for Health the specific steps being taken to ensure the HSE considers the "time-critical" nature of FA during the current price negotiations for Skyclarys; and if she will make a statement on the matter. [17274/26]
View answer274. Deputy Johnny Guirke asked the Minister for Health regarding the reimbursement of Skyclarys (omaveloxolone), the only approved treatment for Friedreich’s Ataxia (details supplied), the specific steps being taken to ensure the HSE considers the "time-critical" nature of FA during the current price negotiations for Skyclarys; and if she will make a statement on the matter. [17394/26]
View answerI propose to take Questions Nos. 249, 250 and 274 together.
Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices, therefore, I have asked the HSE for an update on this matter.
The HSE has advised that it is committed to providing access to as many medicines as possible, in as timely a fashion as possible, from the resources available (provided) to it.
The HSE robustly assesses applications for pricing and reimbursement to make sure that it can stretch available resources as far as possible and to deliver the best value in relation to each medicine and ultimately more medicines to Irish citizens and patients.
HSE decisions on which medicines are reimbursed by the taxpayer are made on objective, scientific and economic grounds.
There are formal processes which govern applications for the pricing and reimbursement of medicines, and new uses of existing medicines, to be funded and / or reimbursed.
The HSE considers the following criteria prior to making any decision on pricing / reimbursement, in line with the Health (Pricing and Supply of Medical Goods) Act 2013:
(1) The health needs of the public,
(2) The cost effectiveness of meeting health needs by supplying the item concerned rather than providing other health services,
(3) The availability and suitability of items for supply or reimbursement,
(4) The proposed costs, benefits, and risks of the item or listed item relative to therapeutically similar items or listed items provided in other health service settings and the level of certainty in relation to the evidence of those costs, benefits and risks,
(5) The potential or actual budget impact of the item or listed item,
(6) The clinical need for the item or listed item,
(7) The appropriate level of clinical supervision required in relation to the item to ensure patient safety,
(8) The efficacy (performance in trial), effectiveness (performance in real situations) and added therapeutic benefit against existing standards of treatment (how much better it treats a condition than existing therapies) and,
(9) The resources available to the HSE.
In terms of the specific details of the application for pricing and reimbursement of omaveloxolone (Skyclarys®):
The HSE received an application for pricing and reimbursement of omaveloxolone (Skyclarys®) on the 1st August 2024 from Biogen Idec (Ireland) Limited (the applicant) for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older.
• The first step in the process is the submission of a Rapid Review dossier (a clinical and economic dossier) to the National Centre for Pharmacoeconomics (NCPE) for assessment. The HSE commissioned the Rapid Review process on the 2nd August 2024.
• The NCPE Rapid Review assessment report was received by the HSE on the 29th August 2024. The NCPE advised the HSE that a full Health Technology Assessment (HTA) was recommended to assess the clinical effectiveness and cost effectiveness of omaveloxolone compared with the current standard of care.
• The HSE commissioned a full HTA on the 25th September 2024 as per agreed processes.
• The NCPE HTA Report was received by the HSE on the 16th December 2025. The NCPE recommends that omaveloxolone not be considered for reimbursement.
• The HSE Corporate Pharmaceutical Unit (CPU) is the interface between the HSE and the Pharmaceutical Industry in relation to medicine pricing and reimbursement applications.
• The Drugs Group is the national committee which the HSE has in place to make recommendations on the pricing and reimbursement of medicines. The membership of the HSE Drugs Group includes public interest members. Pharmacoeconomic reports are reviewed by the HSE Drugs Group along with the outputs of commercial negotiations, and any patient group submission(s) received. The HSE Drugs Group considers all of the evidence and makes a recommendation to the HSE Senior Leadership Team.
• The decision making authority in the HSE is the HSE Senior Leadership Team. The HSE Senior Leadership Team decides on the basis of all the demands it is faced with (across all services) whether it can fund a new medicine, or new use of an existing medicine, from the resources that have been provided to it in line with the Health (Pricing and Supply of Medical Goods) Act 2013.
This application remains under consideration with the HSE. The HSE cannot make any comment on possible outcomes from the ongoing process.
251. Deputy Ciarán Ahern asked the Minister for Health the way in which the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA Framework Agreement which aims for a 180-day decision timeline are being applied to the HSE’s consideration of Skyclarys, to prevent further delays; and if she will make a statement on the matter. [17275/26]
View answer260. Deputy Ryan O'Meara asked the Minister for Health if she will intervene to ensure that the HSE prioritises a conclusion to the Skyclarys reimbursement negotiations, given that it is the only available treatment for this progressive disease, which can currently be classed as having an ‘unmet need’ as outlined in the National Rare Disease Strategy 2025 – 2030; if the current delay aligns with the "equitable access" promised in the newly launched National Rare Disease Strategy 2025-2030; and if she will make a statement on the matter. [17341/26]
View answer275. Deputy Johnny Guirke asked the Minister for Health regarding the reimbursement of Skyclarys (omaveloxolone), the only approved treatment for Friedreich’s Ataxia (details supplied), the way in which the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA Framework Agreement (which aims for a 180-day decision timeline) are being applied to this specific case, to prevent further delays in addressing the ‘unmet need’,; and if she will make a statement on the matter. [17395/26]
View answer293. Deputy Shay Brennan asked the Minister for Health the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA Framework Agreement (which aims for a 180-day decision timeline) which are being applied to a specific case, to prevent further delays in addressing the ‘unmet need’ with FA. [17454/26]
View answer349. Deputy Michael Lowry asked the Minister for Health if she will intervene to ensure that the HSE prioritises a conclusion to the Skyclarys reimbursement negotiations, given that it is the only available treatment for a progressive disease (details supplied) which currently can be classed as having an ‘unmet need’ as outlined in the National Rare Disease Strategy 2025 – 2030; her views on whether the current delay aligns with the "equitable access" promised in the newly launched National Rare Disease Strategy 2025-2030. [17803/26]
View answer350. Deputy Willie O'Dea asked the Minister for Health if she will provide an update on the process to allow for the reimbursement of Skyclarys, the only approved treatment for Friedreich’s Ataxia (FA); the specific steps being taken to ensure the HSE considers the "time-critical" nature of FA during the current price negotiations for Skyclarys; the way in which the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA Framework Agreement (which aims for a 180-day decision timeline) are being applied to this specific case, to prevent further delays in addressing the ‘unmet need’; and if she will make a statement on the matter. [17862/26]
View answerI propose to take Questions Nos. 251, 260, 275, 293, 349 and 350 together.
The State has successfully negotiated a new Agreement in Principle on the Supply and Pricing of Medicines with IPHA, which will commence from this year and last until the end of 2029. The agreement provides a commitment and a structured process towards achieving a 180-day timeline, for completing health technology assessments (HTA) and reimbursement decisions. The structured process will be implemented over the lifetime of the Agreement.
The Department will ensure implementation of the National Rare Disease Strategy 2025 – 2030, and its vision to ensure that all people living with a rare disease have access to equitable, inclusive, safe and cross-sectoral care throughout their life journey that will enable them to reach their full potential and to live their best lives.
Since the launch of the Strategy, an Implementation Oversight Group has been launched and met in February to begin work planning for the 11 recommendations. As implementation of the Strategy progresses, it is intended that patient representation is a key feature and will be embedded in all structures.
Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices, therefore, I have asked the HSE for an update on this matter.
The HSE has advised that it is committed to providing access to as many medicines as possible, in as timely a fashion as possible, from the resources available (provided) to it.
The HSE robustly assesses applications for pricing and reimbursement to make sure that it can stretch available resources as far as possible and to deliver the best value in relation to each medicine and ultimately more medicines to Irish citizens and patients.
HSE decisions on which medicines are reimbursed by the taxpayer are made on objective, scientific and economic grounds.
There are formal processes which govern applications for the pricing and reimbursement of medicines, and new uses of existing medicines, to be funded and / or reimbursed.
The HSE considers the following criteria prior to making any decision on pricing / reimbursement, in line with the Health (Pricing and Supply of Medical Goods) Act 2013:
(1) The health needs of the public,
(2) The cost effectiveness of meeting health needs by supplying the item concerned rather than providing other health services,
(3) The availability and suitability of items for supply or reimbursement,
(4) The proposed costs, benefits, and risks of the item or listed item relative to therapeutically similar items or listed items provided in other health service settings and the level of certainty in relation to the evidence of those costs, benefits and risks,
(5) The potential or actual budget impact of the item or listed item,
(6) The clinical need for the item or listed item,
(7) The appropriate level of clinical supervision required in relation to the item to ensure patient safety,
(8) The efficacy (performance in trial), effectiveness (performance in real situations) and added therapeutic benefit against existing standards of treatment (how much better it treats a condition than existing therapies) and,
(9) The resources available to the HSE.
In terms of the specific details of the application for pricing and reimbursement of omaveloxolone (Skyclarys®):
The HSE received an application for pricing and reimbursement of omaveloxolone (Skyclarys®) on the 1st August 2024 from Biogen Idec (Ireland) Limited (the applicant) for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older.
• The first step in the process is the submission of a Rapid Review dossier (a clinical and economic dossier) to the National Centre for Pharmacoeconomics (NCPE) for assessment. The HSE commissioned the Rapid Review process on the 2nd August 2024.
• The NCPE Rapid Review assessment report was received by the HSE on the 29th August 2024. The NCPE advised the HSE that a full Health Technology Assessment (HTA) was recommended to assess the clinical effectiveness and cost effectiveness of omaveloxolone compared with the current standard of care.
• The HSE commissioned a full HTA on the 25th September 2024 as per agreed processes.
• The NCPE HTA Report was received by the HSE on the 16th December 2025. The NCPE recommends that omaveloxolone not be considered for reimbursement.
• The HSE Corporate Pharmaceutical Unit (CPU) is the interface between the HSE and the Pharmaceutical Industry in relation to medicine pricing and reimbursement applications.
• The Drugs Group is the national committee which the HSE has in place to make recommendations on the pricing and reimbursement of medicines. The membership of the HSE Drugs Group includes public interest members. Pharmacoeconomic reports are reviewed by the HSE Drugs Group along with the outputs of commercial negotiations, and any patient group submission(s) received. The HSE Drugs Group considers all of the evidence and makes a recommendation to the HSE Senior Leadership Team.
• The decision making authority in the HSE is the HSE Senior Leadership Team. The HSE Senior Leadership Team decides on the basis of all the demands it is faced with (across all services) whether it can fund a new medicine, or new use of an existing medicine, from the resources that have been provided to it in line with the Health (Pricing and Supply of Medical Goods) Act 2013.
This application remains under consideration with the HSE. The HSE cannot make any comment on possible outcomes from the ongoing process.
252. Deputy Sean Fleming asked the Minister for Health the number of patients/residents in a location and the number of staff associated with the long stay patient unit at Abbeyleix Community Nursing Home, Abbeyleix, County Laois; and if she will make a statement on the matter. [17281/26]
View answerAs this is a service matter, I have asked the Health Service Executive to respond to the Deputy directly, as soon as possible.
253. Deputy Ryan O'Meara asked the Minister for Health further to Parliamentary Question No. 1147 of 10 February 2026, which advised that “there are currently no plans to establish a SATU in Limerick”, the data and information used to establish this position; the way in which demand for SATU is generally monitored; and the way in the case of Limerick and the surrounding area local demand is monitored; and if she will make a statement on the matter. [17305/26]
View answerAs this is a service matter, I have asked the Health Service Executive to respond to the Deputy directly, as soon as possible.
254. Deputy Ryan O'Meara asked the Minister for Health further to Parliamentary Question No. 1147 of 10 February 2026, given options for storage of evidence are not provided in Limerick’s local out-of-hours Forensic Medical Examination (FME) service, the way in which individuals in the area who wish to store evidence to give them time to consider their reporting intentions are facilitated, as there is no dedicated SATU service in the area; and if she will make a statement on the matter. [17306/26]
View answerAs this is a service matter, I have asked the Health Service Executive to respond to the Deputy directly, as soon as possible.
255. Deputy Ryan O'Meara asked the Minister for Health further to Parliamentary Question No. 1147 of 10 February 2026, given health checks are not provided in Limerick’s local out-of-hours Forensic Medical Examination (FME) service, the way in which individuals who wish to receive a health check are facilitated in the area, as there is no dedicated SATU service in the area; and if she will make a statement on the matter. [17307/26]
View answerAs this is a service matter, I have asked the Health Service Executive to respond to the Deputy directly, as soon as possible.
256. Deputy Ryan O'Meara asked the Minister for Health further to Parliamentary Question No. 1147 of 10 February 2026, to clarify the reason that on the HSE website Limerick’s out-of-hours service is listed alongside actual SATUs when it is actually a Forensic Medical Examination (FME) service and does not provide a comparable service (details supplied); the reason this differentiation in service is not clearly stated on the website for individuals seeking information on SATU services; and if she will make a statement on the matter. [17308/26]
View answerAs this is a service matter, I have asked the Health Service Executive to respond to the Deputy directly, as soon as possible.
